Froedtert & MCW health network is the first in the state to use Duopa™, a new approach to the administration of carbidopa and levodopa for the treatment of motor fluctuations for people with advanced Parkinson's disease.
As Parkinson's disease progresses, some patients may experience motor fluctuations from an "on" state, when symptoms are well-treated, to an "off” state, during which they are slower, stiffer and experience more difficulty moving. These states correspond to peak (on) and trough (off) plasma concentrations of levodopa. Patients may also experience dyskinesias (involuntary movements), generally at peak dose.
Duopa™ was approved by the FDA in 2015 as an enteral suspension for the treatment of these motor fluctuations for people with advanced Parkinson's disease.
How Does Duopa™ Work?
Duopa™ is administered using a small, portable infusion pump that delivers carbidopa/ levodopa directly into the small intestine via a tube placed by a percutaneous endoscopic gastrostomy procedure with a jejunal extension (PEG-J). Duopa™ provides patients with the same active ingredients as orally-administered carbidopa/levodopa immediate release, but is delivered in a continuous fashion throughout the day, which avoids the plasma level peaks and troughs seen with the oral medication.
While there is no known cure for Parkinson’s disease, available treatments help reduce symptoms, and carbidopa/levodopa is recognized as one of the most effective treatment for the disease.